Fractyl-Logo.png
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
29 mai 2024 07h00 HE | Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Casey House
Casey House creates fictitious drug, Stigmavir, to smash HIV stigma within the health care system
29 mai 2024 06h30 HE | Casey House
TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Casey House – a hospital unlike any other providing care to those living with and at risk of HIV – today announces the launch of its latest advocacy campaign,...
NodThera_logo.jpg
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
28 mai 2024 07h00 HE | NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
July 30, 2021 - ROSEN LOGO.jpg
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
27 mai 2024 10h31 HE | The Rosen Law Firm PA
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and...
zealand_logo_RGB_01.png
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
23 mai 2024 14h45 HE | Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
202306_Press Release-Amplify.png
Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR)
21 mai 2024 07h00 HE | Amplify ETFs
Amplify ETFs announces the launch of the Amplify Weight Loss Drug & Treatment ETF (NYSE: THNR).
Fractyl-Logo.png
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
20 mai 2024 06h00 HE | Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Global Digital Health For Obesity Market
Digital Health for Global Obesity Market Analysis Report 2024-2030, Featuring MyFitnessPal, Teladoc, FitnessKeeper, PlateJoy, Tempus, Fitbit, Noom, WellDoc, Sidekick Health and BioAge Labs
14 mai 2024 08h32 HE | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Digital Health For Obesity Market Size, Share & Trends Analysis Report By Component (Hardware, Software, Services), By End-use (Patients, Providers,...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
14 mai 2024 07h57 HE | ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.